Technical Analysis for AVCT - Avacta Group Plc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 122.50 | 0.00% | 0.00 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Support | Bullish | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Earnings Movers | Other | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
20 DMA Support | Bullish | 0.00% | |
200 DMA Support | Bullish | 0.00% | |
Earnings Movers | Other | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Possible Inside Day | 1 day ago |
Possible NR7 | 1 day ago |
Down 2% | 2 days ago |
Fell Below 200 DMA | 2 days ago |
1.5x Volume Pace | 2 days ago |
Free Daily (Stock) Chart Reading
Avacta Group Plc Description
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: Biotechnology Medicine Tools Science Life Sciences Branches Of Biology Clinic Medical Specialties Oncology Immunology Antibodies Immune System Disorders Assay Aptamer Synthetic Antibody
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 187.98 |
52 Week Low | 87.9925 |
Average Volume | 1,321,914 |
200-Day Moving Average | 121.12 |
50-Day Moving Average | 107.59 |
20-Day Moving Average | 117.39 |
10-Day Moving Average | 123.40 |
Average True Range | 7.82 |
RSI (14) | 57.45 |
ADX | 17.98 |
+DI | 24.69 |
-DI | 18.20 |
Chandelier Exit (Long, 3 ATRs) | 112.53 |
Chandelier Exit (Short, 3 ATRs) | 123.52 |
Upper Bollinger Bands | 134.58 |
Lower Bollinger Band | 100.20 |
Percent B (%b) | 0.65 |
BandWidth | 29.28 |
MACD Line | 5.02 |
MACD Signal Line | 5.00 |
MACD Histogram | 0.0207 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 127.81 | ||||
Resistance 3 (R3) | 127.57 | 125.55 | 126.93 | ||
Resistance 2 (R2) | 125.55 | 124.20 | 125.68 | 126.63 | |
Resistance 1 (R1) | 124.03 | 123.37 | 124.27 | 124.27 | 126.33 |
Pivot Point | 122.01 | 122.01 | 122.14 | 122.14 | 122.01 |
Support 1 (S1) | 120.49 | 120.66 | 120.73 | 120.73 | 118.67 |
Support 2 (S2) | 118.47 | 119.83 | 118.60 | 118.37 | |
Support 3 (S3) | 116.95 | 118.47 | 118.08 | ||
Support 4 (S4) | 117.19 |